Similarly, in high-risk atherosclerosis patients with CKD, treatment with canakinumab, an IL-1β neutralising antibody, had no beneficial effect on kidney function, but significantly reduced major adverse cardiovascular events [72]. This evidence concerns the gene IL1B and chronic kidney disease.